Trinity Biotech
TRIB
44 hedge funds and large institutions have $72.9M invested in Trinity Biotech in 2018 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 44 → 44 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
3.13% less ownership
Funds ownership: 72.88% → 69.75% (-3.1%)
29% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 14
60% less capital inflows, than outflows
Capital inflows: $2.12M | Capital outflows: $5.29M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adirondack Research & Management
Guilderland,
New York
|
+$504K |
| 2 |
Renaissance Technologies
New York
|
+$417K |
| 3 |
White Pine Capital
Bloomington,
Minnesota
|
+$274K |
| 4 |
FM
Fondren Management
Houston,
Texas
|
+$168K |
| 5 |
First Wilshire Securities Management
Pasadena,
California
|
+$144K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
-$2.09M |
| 2 |
Heartland Advisors
Milwaukee,
Wisconsin
|
-$1.49M |
| 3 |
Millennium Management
New York
|
-$888K |
| 4 |
Cove Street Capital
El Segundo,
California
|
-$473K |
| 5 |
Teton Advisors
Rye,
New York
|
-$75.8K |
TRIB Hedge Fund Activity: Q2 2018 in Review
44 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q2 2018, worth a combined $72.9M — down 7.1% from $78.4M a quarter earlier.
Fund positioning in TRIB was balanced in Q2 2018: 4 funds opened new positions, 4 closed out, 10 added to existing stakes and 14 trimmed.
The largest buyer was Adirondack Research & Management, adding an estimated $504K. The largest seller was Russell Investments Group, cutting an estimated $2.09M.
- 44 institutional investors held Trinity Biotech (TRIB) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $72.9M of Trinity Biotech stock for Q2 2018, down 7.1% quarter-over-quarter.
- 4 funds opened new Trinity Biotech positions in Q2 2018 and 4 closed out, a net change of 0 holders.
- The largest Trinity Biotech buyer in Q2 2018 was Adirondack Research & Management, an estimated $504K added.
- The largest Trinity Biotech seller in Q2 2018 was Russell Investments Group, an estimated $2.09M sold.
Based on aggregated 13F filings for Q2 2018.